Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE‐PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution

Background Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult‐onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE‐PC), a pediatric‐aimed regimen designed to reduce late effects. We aimed to describe the single‐institution experience of using both regimens in patients with pediatric HL. Methods This retrospective cohort study evaluated a total of 224 patients diagnosed with HL between 1999 and 2018 at Children's Hospital Los Angeles (CHLA), of which 93 patients were eligible having received ABVD (n = 46) or ABVE‐PC (n = 47) chemotherapy as their initial treatment. Descriptive analyses were performed using the Student's t‐test or Fisher's exact test. Survival analysis used the Kaplan–Meier method. Events included death, relapse, and secondary malignancy. We also describe the use of radiation therapy, pulmonary toxicity, and cardiomyopathy determined by shortening fraction